The Genomic Giant: Can GeneDx Revolutionize Your Investment Portfolio by 2025?
GeneDx Holdings Corp. (NASDAQ: WGS) specializes in genetic testing and diagnostics for rare and hereditary conditions, positioning itself as a leader in personalized medicine. In 2022, the company experienced significant financial success, with fourth-quarter revenues exceeding $95 million and gross margins reaching
